Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom

HIV Medicine

Volumn 18, Issue 3, 2017, Pages 204-213

  Tostevin, A ^a   White, E ^a   Dunn, D ^a   Croxford, S ^b   Delpech, V ^b   Williams, I ^c   Asboe, D ^d   Pozniak, A ^d   Churchill, D ^e   Geretti, A M ^f   Pillay, D ^a,g   Sabin, C ^a   Leigh Brown, A ^h   Smit, E ⁱ   Aitken, Celia ^j   Cane, Patricia ^j   Chadwick, David ^j   Clark, Duncan ^j   Collins, Simon ^j   Douthwaite, Samuel ^j   Fearnhill, Esther ^j   Porter, Kholoud ^j   Fraser, Christophe ^j   Hale, Antony ^j   Hué, Stéphane ^j   Kaye, Steve ^j   Kellam, Paul ^j   Lazarus, Linda ^j   Mbisa, Tamyo ^j   Mackie, Nicola ^j   Moses, Samuel ^j   Orkin, Chloe ^j   Nastouli, Eleni ^j   Phillips, Andrew ^j   Templeton, Kate ^j   Tilston, Peter ^j   Zhang, Hongyi ^j   Fairbrother, Keith ^j   Greatorex, Jane ^j   O'Shea, Siobhan ^j   Mullen, Jane ^j   Cox, Alison ^j   Tandy, Richard ^j   Fawcett, Tracy ^j   Hopkins, Mark ^j   Ashton, Lynne ^j   Booth, Clare ^j   Garcia Diaz, Ana ^j   Shepherd, Jill ^j   Schmid, Matthias L ^j   Payne, Brendan ^j   Pereira, Spiro ^j   Hubb, Jonathan ^j   Kirk, Stuart ^j   Gunson, Rory ^j   Bradley Stewart, Amanda ^j   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e Worthing Hospital   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^j NONE

more..

Author keywords

drug resistance; HIV 1; mutations; transmitted; transmitted drug resistance; transmitted drug resistance mutations

Indexed keywords

EFAVIRENZ; INTEGRASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ANTIRETROVIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; FEMALE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEN WHO HAVE SEX WITH MEN; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVERTANT; TREND STUDY; UNITED KINGDOM; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; ADOLESCENT; ANTIVIRAL RESISTANCE; COHORT ANALYSIS; DISEASE TRANSMISSION; DRUG EFFECTS; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREVALENCE; UNITED KINGDOM; YOUNG ADULT;

EID: 84994415935     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12414     Document Type: Article

References (32)

1. Dolling D NM, Schwenk A, Churchill D, Pillay D, Dunn D, UK HIV Drug Resistance Database, UK Collaborative HIV Cohort Study. Rapid increase in the frequency of wild-type HIV-1 drug resistance reports among ART-experienced patients in the UK. Conference on Retroviruses and Opportunistic Infections (CROI). 2013; Abstract 594.
2. Wittkop L, Gunthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363–371.
3. Asboe D, Aitken C, Boffito M et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012; 13: 1–44.
4. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13: 77–108.
5. Chilton DN, Castro H, Lattimore S et al. HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther 2010; 15: 985–991.
6. Dolling D, Sabin C, Delpech V et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 2012; 345: e5253.
7. Frentz D, van de Vijver D, Abecasis A et al. Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLoS One 2014; 9: e94495.
8. Buchacz K, Young B, Palella FJ Jr, Armon C, Brooks JT. Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011. J Antimicrob Chemother 2015; 70: 2337–2346.
9. Young B, Fransen S, Greenberg KS et al. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011; 16: 253–256.
10. Boyd SD, Maldarelli F, Sereti I et al. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther 2011; 16: 257–261.
11. Volpe JM, Ward DJ, Napolitano L et al. Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection. J Int Assoc Provid AIDS Care 2015; 14: 398–401.
12. Johnson VA, Calvez V, Gunthard HF et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013; 21: 6–14.
13. Garcia-Diaz A, McCormick A, Booth C et al. Analysis of transmitted HIV-1 drug resistance using 454 ultra-deep-sequencing and the DeepChek((R))-HIV system. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19752.
14. Stekler JD, McKernan J, Milne R et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 2015; 20: 77–80.
15. Volpe JMYO, Petropoulos CJ, Walworth CM. Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection. ICAAC 2015, September 17-21, 2015, San Diego. 2015.
16. Frange P, Assoumou L, Descamps D et al. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies. J Antimicrob Chemother 2015; 70: 2084–2089.
17. UK Collaborative HIV Cohort Study Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5: 115–124.
18. https://www.gov.uk/guidance/hiv-surveillance-systems#hiv-and-aids-reporting-system-hars (accesses 15 March 2016).
19. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
20. Mitsuya Y, Varghese V, Wang C et al. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol 2008; 82: 10747–10755.
21. Churchill D, Waters L, Ahmed N et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. http://www.bhiva.org/HIV-1-treatment-guidelines.aspx (accessed 15 March 2016).
22. https://www.gov.uk/government/statistics/hiv-data-tables (accessed 15 March 2016).
23. Monge S, Guillot V, Alvarez M et al. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. PLoS One 2014; 9: e90710.
24. Vega Y, Delgado E, Fernandez-Garcia A et al. Epidemiological Surveillance of HIV-1 transmitted drug resistance in Spain in 2004–2012: relevance of transmission clusters in the propagation of resistance mutations. PLoS One 2015; 10: e0125699.
25. Pineda-Pena AC, Schrooten Y, Vinken L et al. Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic. PLoS One 2014; 9: e101738.
26. Castro H, Pillay D, Cane P et al. Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 2013; 208: 1459–1463.
27. Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA. Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom. Clin Infect Dis 2015; 61: 829–836.
28. Schmidt D, Kollan C, Fatkenheuer G et al. Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany. PLoS One 2014; 9: e104474.
29. Yang WL, Kouyos R, Scherrer AU et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the swiss HIV cohort study from 1998 to 2012. J Infect Dis 2015; 212: 28–38.
30. Dolling D, Phillips AN, Delpech V et al. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med 2012; 13: 309–314.
31. Mourad R, Chevennet F, Dunn DT et al. A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK. AIDS 2015; 29: 1917–1925.
32. Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther 2011; 16: 137–140.